Levorotatory Epinephrine Formulation pH and Sterilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of epinephrine suffer from racemization and oxidation, leading to reduced potency and undesirable effects due to the presence of impurities like d-epinephrine and adrenalone, and the use of preservatives like sulfites can cause allergic reactions and safety issues.
Innovation Solution
The development of preservative-free and sulfite-free pharmaceutical formulations of levorotatory-epinephrine, achieved through a manufacturing process involving initial filtration, terminal heat sterilization, and aseptic conditions, with a revised pH range of 2.8 to 3.3 to minimize racemization and oxidation, using l-epinephrine hydrochloride as the active ingredient and sodium chloride as a tonicity agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisulfite antioxidants are added to prevent oxidation, then oxidation is reduced, but allergic reactions and anaphylaxis risk increase
Solution Approach 1:
The patent removes bisulfite antioxidants from the epinephrine formulation entirely, extracting the harmful component while maintaining oxidation prevention through alternative means (inert atmosphere packaging and controlled storage conditions). This resolves the contradiction by eliminating the allergen while preserving the protective function through different mechanisms.
Solution Approach 2:
The patent uses inert atmosphere packaging (nitrogen or other inert gases) to prevent oxidation of epinephrine without requiring bisulfite antioxidants. This creates a protective environment that prevents oxidation while avoiding the harmful allergic reactions associated with sulfites.
2Reliability
If overages are increased to compensate for degradation, then potency is maintained, but side effects and toxicity increase
Solution Approach 1:
The patent performs preliminary stabilization by adjusting the pH to 2.8-3.3 and using inert atmosphere packaging before the degradation occurs. This preliminary protective action maintains potency throughout shelf life without requiring excessive overages, thereby avoiding increased side effects and toxicity from high initial concentrations.
Solution Approach 2:
The patent changes the pH parameter to the optimized range of 2.8-3.3, which slows degradation rates. This parameter change allows for lower overages while maintaining potency, thereby reducing the risk of side effects and toxicity associated with higher drug concentrations.
3Reliability
If terminal heat sterilization is applied, then sterility is ensured, but racemization increases
Solution Approach 1:
The patent performs preliminary sterilization during manufacturing under controlled conditions, and then uses inert atmosphere packaging to maintain sterility without requiring aggressive terminal heat sterilization. This preliminary protective action ensures sterility while minimizing the racemization that would result from high-temperature sterilization.
Solution Approach 2:
The patent uses a composite approach combining chemical stabilization (pH adjustment to 2.8-3.3) with physical protection (inert atmosphere packaging). This composite strategy ensures both sterility and minimal racemization by layering multiple protective mechanisms rather than relying on a single aggressive sterilization method.
4Reliability
If pH is lowered to prevent oxidation, then oxidation is reduced, but racemization increases
Solution Approach 1:
The patent optimizes the pH parameter to the specific range of 2.8-3.3, which is higher than traditional formulations. This parameter change balances both oxidation resistance and racemization prevention, achieving both goals simultaneously rather than creating a trade-off between them.
Solution Approach 2:
The patent uses a composite approach combining moderate pH adjustment (2.8-3.3) with inert atmosphere packaging. This combination allows for better oxidation protection than pH alone while avoiding the excessive racemization that would result from low pH, thereby achieving both oxidation resistance and enantiomeric purity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a more potent and less toxic epinephrine formulation with greater than 90% l-epinephrine content throughout its shelf-life, reduced impurities, and minimal overages, ensuring safer and more reliable medicinal use with a shelf-life of at least 12 months.
Implementation Method 1
terminal heat sterilization
Implementation Method 2
oxidation of epinephrine can be prevented to a certain extent, including the use of antioxidants
Implementation Method 3
Racemization is the enantiomeric conversion of l-epinephrine into its less biologically active dextrorotatory isoform, d-epinephrine
Data Source
AI summary
The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine.